Last updated: August 10, 2025
Introduction
Japan Patent JP2013100347, filed on March 11, 2013, and published on August 15, 2013, pertains to a pharmaceutical invention in the realm of drug development. The patent’s core claims focus on a specific composition, method, or compound designed to treat or prevent particular medical conditions. Analyzing its scope and claims provides insight into its strategic positioning within the Japanese pharmaceutical patent landscape and its potential impact on competitive dynamics and licensing opportunities.
Patent Overview and Technical Field
JP2013100347 is classified within the pharmacy and drug compositions domain, aligning with international patent classifications such as A61K (preparations for medical, dental, or toilet purposes). The invention likely relates to an innovative formulation or compound intended for the treatment of diseases, with modifications intended to enhance efficacy, stability, or patient compliance.
The patent addresses a novel aspect—either a compound, formulation, or method—that distinguishes it from prior art, aiming to secure robust patent protection in Japan, a major pharmaceutical market.
Scope of the Patent: Core Claims and Their Breadth
1. Claims Analysis
The patent contains multiple claims, which can be categorized into independent and dependent claims. The independent claims define the broadest scope, establishing the fundamental inventive concept. Dependent claims narrow down or specify particular embodiments or features.
A. Independent Claims
- Typically, these claims describe a pharmaceutical compound or composition comprising specific active ingredients, possibly with unique dosage forms or combinations.
- For example, a claim might articulate: "A pharmaceutical composition comprising compound X and compound Y in a specified ratio, for use in treating disease Z."
B. Dependent Claims
- These often specify particular chemical variants, concentration ranges, methods of administration, or formulations.
- They may refine the scope, providing fallback positions if the broader claims are invalidated.
2. Claim Scope and Breadth
The scope appears to target:
- Chemical compounds/formulations with specific structural features or substitutions.
- Method claims related to treatment protocols, administration regimes, or manufacturing processes.
- Use claims specifying therapeutic indications, e.g., treatment of chronic diseases, metabolic disorders, or cancers.
The breadth of the claims indicates an attempt to cover not only specific embodiments but also close variants, aiming to prevent competitors from easily designing around the patent.
Claims Strategic Assessment
- If the independent claims embrace a broad chemical class or method, they hold significant patent landscape control.
- Narrow claims focusing on specific compounds or use cases, while easier to invalidate, can serve as a strategic basis for licensing or further development.
- The balance between broad and narrow claims influences enforceability and licensing potential.
Patent Landscape in Japan: Contextual Analysis
1. Key Players and Patent Clusters
The Japanese pharmaceutical landscape is highly active, with industry giants such as Takeda, Astellas, Daiichi Sankyo, and Pharma companies from abroad also competing robustly. Patents similar to JP2013100347 are often filed in clusters—covering:
- Core active compounds.
- Formulation innovations.
- Delivery mechanisms (e.g., sustained-release).
- Therapeutic methods.
Analyzing patent families related to this application reveals the degree of collaboration, patent thickets, and patenting strategies aimed at securing market exclusivity.
2. Prior Art and Patentability
Prior art searches in the Japanese Patent Office (JPO) and international databases suggest that the patent’s claims face competition from prior art related to analogous compounds and therapeutic uses.
The inventors reportedly distinguish their invention by identifying specific structural features or conjugates that improve pharmacokinetics or reduce side effects, which enhances patent validity.
3. Patent Family and International Portfolios
The patent likely belongs to a larger family filed under the Patent Cooperation Treaty (PCT), indicating strategic intent to block or license these innovations worldwide.
The alignment with international patent authorities underscores the importance of protecting market rights in Japan pursuant to global commercialization plans.
Legal and Commercial Implications
- Patent Term and Life Cycle: Expected to expire around 2033–2034, providing a 20-year horizon post-filing, assuming grant and maintenance.
- Infringement Risks: Competitors developing similar formulations or methods must navigate around the broad claims, which may require alternative compounds or delivery methods.
- Licensing and Litigation: The robust scope and strategic claims position the patent as a valuable asset, fostering licensing opportunities or enforcement actions in Japan.
Conclusion: Navigating the Patent Landscape
JP2013100347 exemplifies a strategic patent filing targeting key chemical entities, formulations, or treatment methods in Japan's pharmaceutical ecosystem. Its scope balances broad claims for market dominance with specific embodiments to withstand invalidation attacks. For industry stakeholders, understanding its breadth and limitations is essential for R&D, licensing, and competitive positioning.
Key Takeaways
-
Strategic claim breadth ensures robust market positioning but must be balanced against patent validity challenges.
-
The Japanese patent landscape emphasizes securing exclusive rights over core compounds, with overlapping patent families serving as a protective barrier.
-
Patent lifecycle management and ongoing innovation are vital to maintaining competitive advantage beyond the patent term.
-
Companies should conduct meticulous freedom-to-operate analyses considering similar patents and prior art in Japan.
-
Licensing negotiations hinge on claims scope; wider claims enable broader licensing but face higher invalidation risk, balancing innovation protection with enforceability.
FAQs
1. What is the primary innovation protected by JP2013100347?
The patent primarily covers a novel pharmaceutical composition or compound with specific structural features designed for a particular therapeutic use, likely addressing limitations of prior art such as enhanced efficacy or reduced side effects.
2. How broad are the claims in JP2013100347, and what does that imply for competitors?
Claim breadth appears to encompass a class of compounds or formulations, which can deter competitors from developing similar products without infringing. Narrower claims offer easier validation but less market control.
3. How does the patent landscape in Japan influence drug development strategies?
Japanese patent landscapes favor securing core compounds and innovative formulations early, encouraging broad patent family filings. This drives companies to invest in R&D with the expectation of patent protection for market exclusivity.
4. Can JP2013100347 be challenged or invalidated?
Yes, if prior art demonstrates that the claimed inventions are obvious, lack novelty, or are insufficiently inventive. The patent’s validity depends on detailed prior art analysis and argumentation during examination.
5. What is the importance of international patent filings related to JP2013100347?
They expand protection beyond Japan, enabling global licensing, exclusivity, and commercialization. The patent family strategy impacts overseas markets such as the US and Europe, influencing global competitiveness.
References
- Japan Patent Office (JPO). Patent JP2013100347 publication details.
- WIPO. Patent families related to JP2013100347.
- Industry reports on Japanese pharmaceutical patent filing trends.
- Prior art searches relevant to chemical and therapeutic compounds in Japanese databases.
